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Summary 
 
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder 
clinically characterized by memory loss and cognitive decline. Neuropathological hallmarks 
in AD are the protein depositions of senile plaques and neurofibrillary tangles (NFTs), which 
are composed of amyloid-β (Aβ) and tau protein, respectively. These protein deposits show 
spatiotemporally different distribution in the brain and play different roles in pathophysiology 
of AD. Tau deposition is more closely related to neurodegeneration and cognitive deficits in 
AD than Aβ deposition and thought to begin before extensive neuronal loss and cognitive 
decline occur. Thus, a non-invasive method for measuring tau load in the brain would allow 
us to predict future cognitive decline in the preclinical stages of AD and track disease 
progression. In this thesis, I characterized the binding and pharmacokinetic profiles of novel 
2-arylquinoline derivatives, [18F]THK-523, [18F]THK-5105 and [18F]THK-5117, as potential 
candidates for selective tau radiotracer. In Chapter 1, the binding characteristics of 
[18F]THK-523 was compared with that of amyloid imaging radiotracers such as [11C]PiB, 
[11C]BF-227 and [18F]FDDNP in the same experimental conditions. As a result, 
[18F]THK-523 showed high binding affinity and selectivity for tau pathology and was clearly 
differentiated from other amyloid imaging radiotracers. In Chapter 2, I further evaluated the 
binding and pharmacokinetic profiles of 2 optimized compounds, [18F]THK-5105 and 
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[18F]THK-5117, as candidates for selective tau radiotracer. These tracers showed higher 
binding affinity for tau protein fibrils than [18F]THK-523 and high binding selectivity for 
NFTs in AD brain sections. These radiotracers additionally showed high amount of brain 
uptake and rapid washout after intravenous injection in mice. In conclusion, these findings 
suggested that [18F]THK-5105 and [18F]THK-5117 should be considered as promising 
candidates for selective tau imaging radiotracer. 
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Introduction 
 
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative 
disorder, clinically characterized by memory loss and cognitive decline. AD is the most 
common causes of dementia in the elderly. According to a recent report on the economic 
implications of the impending epidemic of AD, more than 13.5 million individuals just in the 
United States will manifest AD dementia by the year 2050. 1) Although the majority of patient 
with AD is sporadic, three genes such as amyloid precursor protein (APP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2) mutations have linked to autosomal dominant, early-onset 
familial AD. The ε4 allele of apolipoprotein E is strongly implicated in late-onset sporadic AD. 
All these genes affect amyloid-β (Aβ) metabolism such as production and clearance. 2) From 
these evidences, the most widely supported molecular mechanism in AD pathophysiology is 
‘the amyloid cascade hypothesis, 3) which describes the abnormalities in the production or 
clearance of Aβ triggers the aggregation, resulting in the formation Aβ plaques, followed by 
the formation of neurofibrillary tangles (NFTs), leading to synaptic dysfunction and 
eventually neuronal death. 
The major neuropathological hallmarks in AD are senile plaques (SPs) and 
neurofibrillary tangles (NFTs) (Fig. 1). SPs (Fig. 1a) are composed of Aβ, a 39-43 amino acid 
peptide product derived from the sequential proteolytic cleavage of APP by β- and γ-secretase. 
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Familial AD such as carriers of the mutations of APP, PSEN1, and PSEN2 genes lead to 
overproduction of AβX-42, which is the predominant Aβ species in SP of the AD brain.  AβX-42 
is more prone to aggregate rather than AβX-40 in vitro and in vivo. 4), 5) SPs are 
morphologically diverse. NFTs (Fig. 1b) are composed of hyperphosphorylated tau, a 
microtubule-associated protein that physiologically stabilizes microtubule assembly in axon. 
6) Ultrastructurally, twisted filaments of hyperphosphorylated tau in AD are called paired 
helical filaments (PHFs). Tau pathology is also recognized as neuropil threads and dystrophic 
neurites surrounding to senile plaques in the AD brain. Tau aggregates are mainly intracellular, 
but they are also found in extracellular types. These extracellular NFTs are called ‘ghost 
tangle’. These neuropathological hallmarks separately, temporally, and spatially, occur in the 
brain. NFTs occur in the mesial temporal lobe, in particular, the amygdala, hippocampus, 
parahippocampal gyrus, temporal association cortex, while senile plaques are generally 
distributed through the neocortex. 7) The staging of neurofibrillary changes is classified by 
Braak and Braak (Fig. 2). 8), 9) Braak stages I/II (Transentorhinal stage), NFTs predominantly 
occur in the transentorhinal cortex, entorhinal cortex and hippocampus (CA1); stages III/V 
(Limbic stage), NFTs are more abundant in the hippocampus and amygdala while spreading 
slightly in association cortex; stages V/VI (Isocortical stage), NFTs widely distributed through 
the neocortex. Amyloid deposition is also classified by Braak and Thal (Fig. 2). 8), 10), 11) Stage 
A, amyloid deposition begins in basal portion of the isocortex; stage B, amyloid deposition 
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widely spread in all isocortical association area; stage C, all areas of the isocortex including 
sensory and motor area are affected. 
Until now, the clinical diagnosis of AD is based on neuropsychological tests such as Mini 
Mental State Examination (MMSE) and Clinical Dementia Rating (CDR), measuring 
progressive impairment of memory. Structural imaging techniques such as computed 
tomography (CT) and magnetic resonance imaging (MRI) are routinely used in the clinical 
evaluation of AD. MRI can detect cortical atrophy with a thickness of the hippocampus and 
entorhinal cortex. Functional neuroimaging techniques using positron emission tomography 
(PET) and single photon emission computed tomography (SPECT) also assist the clinical 
evaluation of AD. These methods can potentially detect subtle pathophysiological change 
before structural changes occur. SPECT perfusion imaging can detect a decline in the regional 
cerebral blood flow. [18F]Fluorodeoxyglucose (FDG) PET is useful tool to detect the regional 
glucose hypometabolism. FDG PET and SPECT perfusion reductions in the parientotemporal 
association cortex are recognized as a diagnostic pattern of AD, which reflects neuronal 
damage and dysfunction. Cerebrospinal fluid (CSF) biomarkers such as Aβ42, total tau (t-tau), 
and phosphorylated at threonine 181 tau (p-tau) are valuable in the early and differential 
diagnosis of AD, which are the markers directly associated with AD pathology. The reduction 
of CSF Aβ42 correlates with the clinical diagnosis of AD and Aβ neuropathology at autopsy, 
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12), 13), 14) while increased CSF tau correlates with clinical disease severity and the presence of 
NFTs at autopsy. 15)  
At present, there is only symptomatic treatment with acetylcholinesterase inhibitors such 
as donepezil, galantamine, and rivastigmine or a glutamatergic moderator (memantine) in AD 
treatment. These treatments provide modest benefit in some patients, but it is temporary and 
limited effect. There is no approved disease-modifying therapy for AD to slow the rate of 
neurodegeneration at this point. Considerable effort has been focused on the development of 
new classes disease-modifying therapies based on the amyloid cascade hypothesis. 
Amyloid-targeting drugs such as γ-secretase inhibitors/modulators, anti-aggregation drugs, 
and anti-amyloid antibodies are developed. 16) However, many anti-amyloid drugs failed to 
improve symptoms of dementia in clinical trials despite of great expectations. 17), 18) 
Currently, the clinical diagnosis of AD is mainly based on neuropsychological tests. 
However, Aβ plaques and NFTs have already accumulated in the brain of patients at clinical 
stage of dementia. There are several reasons for the failure of clinical trials of anti-amyloid 
drugs. One possible reason is a high rate of misdiagnosis in patient enrolment. A recent 
announcement about the results of solanezumab clinical trial at Alzheimer’s association 
international conference 2013 (AAIC 2013) suggested a substantial percentage of enrolees in 
the clinical trial did not demonstrate the evidence of an abnormal accumulation of brain Aβ, 
which solanezumab is designed to target, so solanezumab did not work. Another possible 
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reason for the failure of clinical trials is the delay of a starting timing of treatment for 
AD-related pathology. 19) To maximize the efficacy of anti-AD drugs, it would be ideal to 
confirm the existence of AD-related pathology before treatment and start treatment as early as 
possible. 
   Recent advances in the development of PET radiotracer targeting to fibrillar Aβ allow us 
to detect Aβ accumulation in the living human brain. Several amyloid-PET tracers including 
[11C]PiB, [18F]FDDNP and [11C]BF-227, have been developed for this purpose (Fig. 3). The 
most widely used amyloid imaging tracer worldwide is Pittsuburgh Compound B (PiB). 
[11C]PiB has shown to possess high affinity and selectivity for fibrillar Aβ and have shown a 
robust difference in the retention between AD patients and age-matched controls. 20), 21) 
Furthermore, postmortem analysis of AD patients who had undergone [11C]PiB PET imaging 
before death suggested a strong correlation between in vivo PiB binding and regional 
distribution of Aβ plaques. 22) To date, there is no practical method to measure the amount of 
tau deposits in the human brain. Tau pathology is closely related to neuronal loss and 
cognitive impairment rather than amyloid pathology. 23), 24), 25), 26) Furthermore, tau deposition 
is thought to begin before extensive neuronal loss and cognitive decline occur (Fig. 
4).Therefore, non-invasive detection of tau pathology in the brain would allow us to predict 
future cognitive decline in preclinical stages of AD and to track disease progression. 27), 28) 
Tau imaging would also be useful to evaluate efficacy of anti-tau treatment.  
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   Several researchers have focused on the development of tau PET radiotracer in the human 
brain. 2-(1-(6-[(2-18F-fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene) Malononitrile 
([18F]FDDNP) is claimed as the only PET tracer that allows measurement of the amount of 
tau aggregates in the human brain. 29), 30) This tracer demonstrated higher regional uptake in 
the mesial temporal lobe and neocortex in AD patients than that in healthy control. However, 
[18F]FDDNP was reported to non-selectively bind to both NFTs and Aβ aggregates. 31), 32) 
There are much more abundant Aβ aggregated compared with PHF-tau (5-20 times) in the 
neocortex of AD brain and they are co-localized in the grey matter of AD brain. Therefore, the 
development of selective tau PET radiotracers is necessary for accurate and quantitative 
evaluation of tau pathology in AD.  
   In the past few years, we have screened many β-sheet binding compounds to develop 
novel radiotracers with high affinity and selectivity for tau aggregates. Consequently, a series 
of novel quinoline derivatives that selectively bind NFTs were identified. Serial analyses of 
these compounds led to the design and synthesis of a novel tau imaging radiotracer 
[18F]THK-523. Through further optimization process, novel 18F-labeled 2-arylquinoline 
derivatives, [18F]THK-5105 and [18F]THK-5117 were developed as promising candidates for 
in vivo tau imaging probes. Tau PET radiotracers require several key properties. 33) Aβ plaques 
and PHF-tau share a common β-sheet secondary structure. Furthermore, there are much more 
abundant of Aβ aggregated compared with PHF-tau in AD brain and they are co-localized in 
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the grey matter of AD brain. Therefore, the binding selectivity of radiotracers for PHF-tau is 
an important characteristic for tau PET radiotracer. These radiotracers also need to have 
sufficient binding affinity (KD < 20 nM) for tau protein fibrils. In vitro saturation binding 
assays and in vitro autoradiography (ARG) are generally used to estimate binding selectivity 
and affinity of radiotracers to Aβ and tau protein fibrils. In addition, radiotracers need to cross 
the blood-brain barrier and wash out rapidly from normal brain tissue. 
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Objective 
 
The objective of this thesis is to characterize the binding and pharmacokinetic profiles of 
novel 2-arylquinoline derivatives, [18F]THK-523, [18F]THK-5105 and [18F]THK-5117 as 
potential candidates for selective tau radiotracer.  
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Chapter 1 
Comparison of the binding characteristics of [18F]THK-523 and 
amyloid imaging tracers in Alzheimer’s disease pathology 
 
Portions of this chapter have been published in European Journal of Nuclear Medicine and 
Molecular Imaging, 40(1):125-132, 2013. Copyright© 2012, Springer 
 
   In this chapter, results of the binding affinity of [18F]THK-523 for in vitro generated Aβ 
and tau fragment fibrils are compared with PiB, BF-227, and FDDNP, to characterize the 
binding properties of THK-523 as a selective tau imaging tracer. 
 
Experimental methods 
Material 
The non-labeled compounds PiB, BF-227, FDDNP, THK-523 and their precursors were 
custom synthesized by Tanabe R&D Service (Osaka, Japan) (Fig. 4). Human Aβ42 was 
purchased from Peptide Institute Inc. (Mino, Japan). Recombinant K18ΔK280-tau protein was 
obtained from Invitrogen (Tokyo, Japan). 
 
Radiolabeling of PiB, BF-227, THK-523 and FDDNP 
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[3H]PiB (specific activity, 2.96 GBq/µmol) was purchased from American Radiolabeled 
Chemicals (Saint Louis, MO). Schemes of Radiosynthesis for [11C]PiB, [11C]BF-227, 
[18F]BF-227, [18F]THK-523, [18F]FDDNP were shown in Fig. 5. Radiolabeling of [11C]PiB 
was performed using its precursor (2-(4-aminophenyl)-6-methoxymethoxybenzothiazole) and 
[11C]methyl triflate, as previously described. 34) , 35) The mean specific activity of [11C]PiB 
was 34.6 GBq/µmol.  
[18F]BF-227 was synthesized by nucleophilic substitution of the tosylate precursor 
(2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(tosyloxy)ethoxy]benzoxazole. After a 
10-minute reaction at 110°C, the crude mixture was partially purified on an activated Sep-Pak 
tC18 cartridge before undergoing semi-preparative reverse phase HPLC purification. Standard 
tC18 Sep-Pak reformulation produced [18F]BF-227 in >95% purity. The radiochemical yield 
was 12–19% (non-decay corrected), and the mean specific activity of [18F]BF-227 was 163 
GBq/µmol at the end of the synthesis. [11C]BF-227 was synthesized using N-desmethylated 
derivatives as its precursor and [11C]methyl triflate, as previously described. 36) The mean 
specific activity of [11C]BF-227 was 136 GBq/µmol. 
[18F]THK-523 was synthesized by nucleophilic substitution of the tosylate precursor 
(2-(4-aminophenyl)-6-(2-tosyloxyethoxy)quinolone) as previously described. 37) The standard 
tC18 Sep-Pak reformulation produced [18F]THK-523 in >95% purity. The radiochemical yield 
was 38–49% (non-decay corrected), and the mean specific activity of [18F]THK-523 was 68 
15 
 
GBq/µmol at the end of the synthesis. Radiolabeling of [18F]FDDNP was performed by the 
nucleophilic substitution of the tosylate precursor 
(2-{[6-(2,2-dicyano-1-methylvinyl)-2-naphthyl](methyl)amino}ethyl-4-methylbenzenesulfon
ate) as previously described. 38) After a 15-minute reaction at 95°C, the crude mixture was 
partially purified on an activated Sep-Pak tC18 cartridge before undergoing semi-preparative 
reverse phase HPLC purification. Standard tC18 Sep-Pak reformulation produced 
[18F]FDDNP in >95% purity. The radiochemical yield was 12–19% (non-decay corrected), 
and the mean specific activity of [18F]FDDNP was 27 GBq/µmol at the end of the synthesis. 
Radiosynthesis was conducted by CYRIC, Tohoku University. 
 
Transmission electron microscopy 
Fibril formation of Aβ42 and K18ΔK280-tau were confirmed by transmission electron 
microcopy following staining with uranyl acetate. Carbon-coated electron microscopy grids 
were coated with Aβ42 or K18ΔK280-tau fibrils. Grids were viewed on a H-7600 transmission 
electron microscope, operating at a voltage of 80 kV. 
 
In vitro radioligand binding assay 
 Synthetic Aβ42 fibrils and K18ΔK280-tau fibrils were prepared as previously described. 
37) For in vitro binding assays, synthetic Aβ42 or K18ΔK280 fibrils (200 nM) were incubated 
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with increasing concentrations of [3H]PiB and 18F-labeled compounds (0.5-200 nM). To 
account for non-specific binding of [3H]PiB and 18F-labeled compounds, the above-mentioned 
reactions were performed in triplicate in the presence of each unlabeled compound at 2 μM. 
The binding reactions were incubated for 1 hour for the 18F-labeled compounds and 3 
hours for [3H]PiB at room temperature, in 200 µL of assay buffer (Dulbecco’s PBS; 0.1% 
BSA). Separation of bound from free radioactivity was achieved by filtration under reduced 
pressure (MultiScreen HTS Vacuum Manifold; MultiScreen HTS 96-well 0.65-µm filtration 
plate, (Millipore, Billerica, MA). The filters were washed 3 times with 200-µL assay buffer, 
and the filters containing the bound 18F-labeled compounds were then assayed for 
radioactivity in a γ-counter (AccuFLEX γ7000, Aloka, Tokyo, Japan). The filters containing 
[3H]PiB were incubated in 2 mL of scintillation fluid (Aquasol-2, PerkinElmer, Boston, MA), 
and the radioactivity of 3H was counted using a beta counter (LS6500 liquid scintillation 
counter, Beckman Coulter, Brea, CA). The binding data were analysed with curve-fitting 
software that calculates the KD and Bmax using non-linear regression (GraphPad Prism Version 
5.0, GraphPad Software, SanDiego, CA). 
 
Autoradiography, immunohistochemistry, and Gallyas silver staining 
Experiments were performed under the regulations of the Ethics Committee of Tohoku 
University Graduate School of Medicine. The frontal and mesial temporal brain sections (6 
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μm thick) of 3 AD patients were incubated with1.0-MBq/mL 11C- and 18F-labeled compounds 
at room temperature for 10 minutes and then washed briefly with water and 50% ethanol. 
After drying, the labeled sections were exposed to a BAS-III imaging plate (Fuji Film, Tokyo, 
Japan) overnight. The autoradiographic images were obtained using a BAS-5000 
phospho-imaging instrument (Fuji Film) with a spatial resolution of 25 × 25 µm. The adjacent 
sections were immunostained using AT8 anti-tau monoclonal antibody (diluted 1:20; 
Innogenetics, Ghent, Belgium) and 6F/3D (diluted 1:50; Dako, Glostrup, Denmark). The 
adjacent sections were also stained by the Gallyas-Braak method, which is considered to be 
NFTs specific as previously reported. 
 
Results 
2-1. Radiosynthesis 
   All labeled compounds ([18F]THK-523, [18F]FDDNP, [18F]BF-227, [11C]BF-227, and 
[11C]PiB) were synthesized in >95% radiochemical purities after HPLC purification. The 
specific activities of 18F-labeled compounds ranged from 27 to 163 GBq/μmol, corrected at 
the end of synthesis. The mean specific activities of [11C]BF-227 and [11C]PiB were 136 
GBq/µmol and 34.6 GBq/µmol, respectively.  
 
2-2. Binding affinity for in vitro generated Aβ and tau fibrils 
To characterise the binding properties of THK-523, PiB, BF-227, and FDDNP, in vitro 
radioligand binding assays for synthetic Aβ42 and truncated tau construct (K18ΔK280) fibrils 
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were performed under the same experimental conditions. Truncated tau construct 
(K18ΔK280) consists of the four repeat regions (244-372) and lacking lysine 280 (ΔK280) 
observed in frontotemporal dementia with parkinsonism linked to chromosome (FTLD-17) 
familial mutation (Fig. 6a). K18ΔK280 tau aggregates exhibited the similar characteristic to 
PHF-tau from AD brain. 39) In addition, K18ΔK280 tau forms aggregate quickly without 
co-factor such as heparin. 40) Thus, K18ΔK280 fibrils were used for in vitro binding assay. 
The successful formation of fibrils was determined by transmission electron microscopy. The 
typical pictures are shown in Fig. 6b. Our analysis indicated that [18F]THK-523 showed a 
higher binding affinity for tau fibrils (KD1 = 1.99 nM, Bmax1 = 1.22 pmol THK-523/nmol 
K18ΔK280-tau) than for Aβ42 fibrils (KD1 = 30.3 nM, Bmax1 = 12.6 pmol THK-523/nmol Aβ42), 
which was similar to previously published data. 37) On the other hand, [3H]PiB bound to Aβ42 
fibrils with high affinity (KD1 = 0.84 nM, Bmax1 = 0.44 pmol PiB/nmol Aβ42). [3H]PiB also 
showed two binding sites for K18ΔK280-tau fibrils, but with a relatively lower affinity (KD1 = 
6.39 nM, Bmax1 = 1.38 pmol PiB/nmol K18ΔK280-tau) than [18F]THK-523. [18F]BF-227 
showed a high binding affinity for Aβ42 fibrils (KD1 = 1.72 nM, Bmax1 = 0.50 pmol 
BF-227/nmol Aβ42), but showed a relatively lower affinity for tau fibrils (KD = 30.2 nM, Bmax 
= 10.7 pmol BF-227/nmol K18ΔK280-tau). [18F]BF-227 had an approximately 20-fold higher 
affinity for the first class of Aβ42 binding sites compared with tau fibrils. Only one class of 
[18F]FDDNP binding site was identified on the Aβ42 (KD = 5.52 nM, Bmax = 0.277 pmol 
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FDDNP/nmol Aβ42) and K18ΔK280 tau fibrils (KD = 36.7 nM, Bmax = 2.14 pmol 
FDDNP/nmol K18ΔK280-tau). These results suggest that [18F]FDDNP binds Aβ42 fibrils with 
relatively lower affinity than [3H]PiB and [18F]BF-227. Furthermore, [18F]FDDNP had an 
approximately 7-fold higher affinity for Aβ42 fibrils than for tau fibrils. These binding profiles 
are significantly different from that of [18F]THK-523 (Table 1). 
 
2-3. In vitro autoradiography of human brain sections 
To compare the binding selectivity of these tracers, in vitro autoradiography were 
performed using the serial sections of the lateral temporal brain sections from an AD patient. 
AD temporal brain sections containing widespread amyloid and tau burdens were used in this 
experiment. Autoradiographic images analyses indicated that [11C]PiB and [11C]BF-227 
diffusely accumulated in the grey matter (Fig. 7a, c). The regional distribution of these tracers 
in autoradiograms closely resembles that of Aβ immunohistochemistry (Fig. 7b). In contrast, 
[18F]THK-523 tends to accumulate in the inner layer of grey matter, which correlated well 
with tau immunostaining in the adjacent brain section (Fig. 7d, arrwoheads). [18F]FDDNP did 
not significantly accumulate in any region of AD brain section (Fig. 7f), which was consistent 
with previous report. 32) 
To further assess the binding selectivity of [18F]THK-523, in vitro [18F]THK-523 
autoradiography were performed in frontal (Fig. 8) and mesial temporal (Fig. 9) brain sections 
from 3 AD patients, compared with [11C]PiB. While Aβ plaques in the frontal grey matter 
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were labeled with [11C]PiB (Fig. 8a-c), the binding of [18F]THK-523 in the frontal grey matter 
was considerably lower (Fig. 8g-i). In the mesial temporal brain sections, [11C]PiB did not 
accumulate in the hippocampal CA1 area (Fig. 9a-c), whereas [18F]THK-523 accumulated in 
this area (Fig. 9g-i). The presence of high density of tau and low density of Aβ in this area 
was confirmed by immunohistochemistry (Fig. 8, 9d-f). Furthermore, the band-like 
distribution of [18F]THK-523 in the inner layer of the temporal grey matter was similar to the 
distribution of tau (Fig. 9j-l). In the high magnification images of case AD3 (Fig. 9m-s), the 
distribution of [18F]THK-523 closely resembled Gallyas silver staining and tau 
immunostaining. [18F]THK-523 binding was observed in the areas showing high density of 
NFTs in the hippocampal CA1, the layer pre-α and pri-α in the entorhinal cortex (ERC) (Fig. 
9m-q). Intriguingly, [18F]THK-523 labeling in the layer pre-α of the ERC corresponded to 
Gallyas silver staining better than tau immunostaining, suggesting the preferential binding of 
[18F]THK-523 to extracellular tau deposits that were clearly visualized by Gallyas silver 
staining. 41) In contrast to [18F]THK-523, the distribution of [11C]PiB was similar to that of Aβ 
immunohistochemistry (Fig 9r-s). [11C]PiB binding corresponded to the formation of amyloid 
in the parvopyramidal layer of the presubicular area and in the layers pre-β and pre-γ of the 
ERC (Fig. 9p, s). 10) 
 
Discussion 
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This study is for the first time provided a direct comparison of the binding properties of the 
novel quinoline derivative THK-523 and other amyloid PET probes. Because tau and Aβ 
aggregates share a common β-sheet secondary structure, these compounds can potentially 
bind all these misfolded proteins. These data suggest the potential utility of THK-523 for the 
selective detection of PHF-tau in the living human brain, which was not previously been 
achieved. The autoradiographic images of the AD brain sections revealed that [18F]THK-523 
successfully labeled PHF-tau deposits but did not label Aβ deposits in the frontal and 
temporal cortices. These findings suggest that [18F]THK-523 is a promising candidate for tau 
imaging tracer and could also be a lead compound for future development of tau-selective 
radiotracers. [18F]THK-523 would show retention in tau-rich brain regions if administered to 
AD patients. However, [18F]THK-523 showed relatively high white matter binding and the 
specific signal of [18F]THK-523 might be lower than those of PiB and BF-227 owing to the 
relatively lower amount of tau deposits in the neocortex of AD patients. 33) Further compound 
optimization may be required to achieve a higher contrast image of PHF-tau deposits. 
From these findings, it is speculated that the binding of these radiotracers depends on the 
conformation of pathological protein aggregates, that is, the radiotracers recognize the 
conformation of protein aggregates. Tau protein and Aβ fibrils share the common 
cross-β-sheet structure, but the atomic structure of these protein aggregates remains elusive. 
Analyses using specific radiotracers will allow us to characterize the structural conformation 
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of these pathological lessons and to better understanding the structural similarity and diversity 
of pathological deposits in various protein misfolding diseases such as AD.  
In vitro saturation binding studies demonstrated that [18F]THK-523 bound with higher 
affinity to tau fibrils (KD1 = 1.99 nM) than to Aβ42 fibrils (KD1 = 30.3 nM), whereas PiB and 
BF-227 showed the opposite binding characteristics. [3H]PiB bound with higher affinity to 
Aβ42 fibrils (KD1 = 0.84 nM) than to tau fibrils (KD1 = 6.39 nM), similar to previous reports, 22, 
42, 43) and [18F]BF-227 had more than a 10-fold higher affinity for Aβ42 fibrils (KD1 = 1.72 nM) 
than for tau fibrils (K18ΔK280; KD1 = 30.2 nM). The autoradiographic images of the AD 
brain sections revealed that [11C]PiB and [11C] BF-227 accumulated in the grey matter of the 
neocortex, which closely resembled the staining pattern of Aβ immunohistochemistry. A 
previous study suggested that [3H]PiB labeled NFTs at tracer concentrations usually achieved 
during a PET scan. 44) However, another study showed no binding of the PiB derivative 
[3H]BTA-1 to plaque-free and NFT-rich ERC homogenates, despite the high amount of 
[3H]BTA-1 binding to frontal cortex homogenates containing plenty of neuritic plaques. 45) 
Autoradiographic and immunohistochemical analyses in this study indicated that PiB 
predominantly binds to SPs but not to NFTs. These findings are consistent with the findings 
from clinical PiB-PET studies showing no remarkable PiB retention in the mesial temporal 
cortex of AD patients. 22) 
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Another radiotracer, [18F]FDDNP, has been reported to detect Aβ and tau pathological 
lesions in AD patients. 29) Previous clinical PET studies showed the higher cortical uptake of 
[18F]FDDNP in the lateral and mesial temporal lobes of AD subjects. 21, 29) Furthermore, a 
multi-tracer PET study of [11C]PiB and [18F]FDDNP showed significant retention of FDDNP 
in the mesial temporal cortex, even if no remarkable retention of PiB in the same region. 46) 
However, in vitro binding studies have reported the limited binding affinity of [3H]FDDNP to 
AD pathological lesions and a previous autoradiographic analysis has suggested that 
[3H]FDDNP does not significantly label any region in the AD brain. 32) Previous in vitro 
binding studies additionally showed the binding affinity of FDDNP for Aβ40 fibrils (KD = 0.12, 
85 nM), 32, 38) but the binding affinity for tau fibrils was not reported. Here, this study showed 
the binding affinity of [18F]FDDNP for tau fibrils (KD1 = 36.7 nM) was similar to that of 
[18F]BF-227 (KD1, 30.2 nM), but much higher than that of [18F]THK-523 (KD1, 1.99 nM). 
In conclusion, the binding profiles of [18F]THK-523, [11C]PiB, [18F]BF-227, and 
[18F]FDDNP were compared using in vitro saturation binding assays and autoradiography of 
AD brain sections. These data suggest that [18F]THK-523 shows binding preference to tau 
protein fibrils. Therefore, [18F]THK-523 is a candidate for radiotracer to identify tau protein 
deposits and a lead compound for future tracer development. Ongoing clinical trials will 
clarify the clinical utility of this tracer and its derivatives for tau imaging in vivo. 
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Chapter 2 
Novel 18F-labeled arylquinoline derivatives for noninvasive 
imaging of tau pathology in Alzheimer disease 
 
Portions of this chapter have been published in Journal of Nuclear Medicine, 
54(8):1420-1427, 2013. Copyright© 2013, Society of Nuclear Medicine and Molecular 
Imaging 
 
   An 2-arylquinoline derivative [18F]THK-523 selectively labeled tau pathology in 
postmortem AD brain sections, as shown in Chapter 1. However, the preclinical data suggest 
that low binding capacity and affinity for postmortem AD brains containing native tau 
deposits, high non-specific binding in the white matter, and insufficient brain uptake in mice, 
indicating the pharmacokinetics and binding characteristics might not reach the optimal levels 
required for PET tracers. Optimization process has identified novel 18F-labeled 
2-arylquinoline derivatives that are promising candidate for in vivo tau imaging probes, 
[6-(3-fluoro-2-hydroxy)propoxy]-2-(4-dimethylaminophenyl)quinoline ([18F]THK-5105) and 
[6-(3-fluoro-2-hydroxy)propoxy]-2-(4-methylaminophenyl)quinoline ([18F]THK-5117). In 
this chapter, preclinical evaluations of binding and pharmacokinetics profiles were performed. 
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Experimental methods 
Material 
The non-labeled THK compounds, FDDNP, PiB and their precursors were custom 
synthesized by Tanabe R&D Service (Osaka, Japan). Human Aβ42 was purchased from 
Peptide Institute Inc. (Mino, Japan). Recombinant K18ΔK280-tau protein was obtained from 
LifeTechnologies (Tokyo, Japan).  
 
Radiolabeling 
18F-labeled 2-arylquinoline derivatives were prepared from the corresponding tosylate 
precursors according to the scheme as indicated in the Fig. 10. Briefly, the aqueous 18F– 
contained in K2CO3 solution (1.59–3.69 GBq) and Kryptofix222 (15 mg) were placed in a 
brown vial. Water was removed by azeotropic evaporation with acetonitrile. After drying, the 
activated 18F-KF/Kryptofix222 was reacted with the precursor (3 mg) in DMSO (0.7 mL) at 
110°C for 10 min. Then, 2 M HCl was added to the solution followed by additional 3 
min-reaction for deprotection of the hydroxyl group. After neutralization with 4 M AcOK, the 
product was purified by semi-preparative high-performance liquid chromatography (HPLC; 
column: Inertsil® ODS-4 (GL Sciences, Inc., Tokyo, Japan); mobile phase: 20 mM 
NaH2PO4/acetonitrile (55/45 for THK-5105 and -5117); flow rate: 5.0 mL/min). The 
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radiolabeled product was dissolved in ethanol, DMSO, or saline with polysobate-80 (<0.1%) 
for biological evaluation. [18F]FDDNP and [11C]PiB was prepared as described in chapter 2. 
Radiosynthesis was conducted by CYRIC, Tohoku University. 
 
Determination of Log P Values 
Determination of Log P values was carried out by HPLC method according to the OECD 
guideline with slight modification. Briefly, 12 reference compounds whose Log P values 
range 7 between 0.5 and 4.0 were analyzed by HPLC under the following conditions; HPLC: 
a JASCOLC-2000 Plus series (JASCO, Tokyo, Japan); column: Inertsil® ODS-4 (4.6 × 150 
mm, 5 μm; GL Sciences, Inc., Tokyo, Japan); mobile phase: 20 mM NaH2PO4 (pH 
7.4)/acetonitrile (55/45); flow rate: 1.5 mL/min; UV absorbance: 245 nm; column 
temperature: 40°C. Then, a calibration curve of Log (tR-t0) (tR: retention time; t0: dead time) 
versus log P of each reference compound was created (R2 = 0.9469). Test compounds listed in 
Table 3 were also analyzed by the same HPLC method to measure Log (tR-t0) values that 
were used for determination of Log P values from the calibration curve. 
 
In vitro radioligand binding assay 
In vitro saturation binding analyses were conducted as previously described in Chapter 2. 
Experiments were performed under the regulations of the Ethics Committee of Tohoku 
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University Graduate School of Medicine. Additionally, AD brain homogenates were prepared 
for in vitro binding assay. Frozen human brain tissue was isolated from temporal grey matter 
of an AD patient and homogenized in PBS. Brain tissue homogenate aliquots were taken and 
frozen at -80°C until used. Insoluble Aβ and tau levels were determined by a human 
β-amyloid enzyme-linked immunosorbent assay (ELISA) kit (Wako) and a human tau ELISA 
kit (LifeTechnologies Japan Ltd), respectively. 
For competitive binding assays, the assay buffer (Dulbecco PBS; 0.1% bovine serum 
albumin) containing each compound (0.1-10,000 nM), [3H]THK-5117 (2 nM), AD brain 
homogenate (100 μg), was incubated at room temperature for 3 h. Nonspecific binding was 
determined in the presence of 2 μM unlabeled THK-5117. Separation of bound from free 
radioactivity was achieved by filtration under reduced pressure (MultiScreen HTS Vacuum 
Manifold; MultiScreen HTS 96-well 0.65-µm filtration plate, (Millipore, Billerica, MA). The 
filters were washed 3 times with 200-µL assay buffer, and the filters containing the 3H-labeled 
compound were incubated in 2 mL of scintillation fluid (Emulsifer-SafeTM, PerkinElmer, 
Boston, MA), and the radioactivity of 3H was counted using a beta counter (LS6500 liquid 
scintillation counter, Beckman Coulter, Brea, CA). All assays were at least triplicate. 
Half-maximal inhibitory concentration values were determined form the displacement curves 
using the GraphPad software v5.01 (GraphPad Software, San Diego CA, USA). Inhibitory 
29 
 
constant (Ki) values were calculated from the half-maximal inhibitory concentration values 
using the Cheng-Prusoff equation. 47) 
 
Tissue staining 
Experiments were performed under the regulations of the Ethics Committee of Tohoku 
University Graduate School of Medicine. Paraffin-embedded hippocampal brain sections 
from an autopsy-confirmed AD case (78-year-old woman) were used for tissue staining with 
THK-5105 and THK-5117. Brain sections were obtained from Fukushimura Hospital 
(Toyohashi, Japan). After deparaffinization, autofluorescence quenching was performed as 
previously described. 48) Quenched tissue sections were immersed for 10 min in 100 μM 
THK-5105 and THK-5117 solution containing 50% ethanol. Sections were then dipped 
briefly into water, rinsed in PBS, coverslipped with FluorSave Reagent (Calbiochem, 
Darmstadt, Germany), and examined using a Nikon Eclipse microscope (Tokyo, Japan) 
equipped with a blue-violet filter (excitation 400–440 nm, dichroic 10 mirror 455 nm, barrier 
filter 470 nm). Sections stained with THK-5105 and THK-5117 were subsequently 
immunostained with the AT8 anti-Tau antibody (Innogenetics, Ghent, Belgium; diluted 1:20). 
Following incubation at 4°C in the primary antibody for 16 h, sections were processed by the 
avidin-biotin method using a Pathostain ABC-POD(M) Kit (Wako) and diaminobenzidine as 
a chromogen.  
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Autoradiography, immunohistochemistry, and Gallyas silver staining 
Paraffin-embedded brain sections from a health control (62-y-old man) and 2 AD patients 
(69-y-old man and 92-y-old woman) were cut with 8 μm and incubated with1.0-MBq/mL 11C- 
and 18F-labeled compounds at room temperature for 10 minutes and then washed briefly with 
water and 50% ethanol. After drying, the labeled sections were exposed to a BAS-III imaging 
plate (Fuji Film, Tokyo, Japan) overnight. The autoradiographic images were obtained using a 
BAS-5000 phospho-imaging instrument (Fuji Film) with a spatial resolution of 25 × 25 µm. 
The adjacent sections were stained using a modified Gallyas-Braak method or immunostained 
with AT8 anti-tau monoclonal antibody (diluted 1:20; Innogenetics, Ghent, Belgium), 6F/3D 
Aβ antibody (diluted 1:50; Dako, Glostrup, Denmark) or 4G8 Aβ antibody (diluted 1:100; 
Signet). For correlation analysis of the autoradiographic and immunohistochemical images, 
36 circular regions of interest (the area of each region of interest was ~7 mm2) were placed on 
the gray matter of the hippocampus, parahippocampal gyrus, fusiform gyrus, temporal gyri 
(superior, middle, and inferior), insula, pre- and postcentral gyri, superior frontal gyrus, 
paracentral lobule, and cingulate gyrus. The percentage area of positive signals in each region 
of interest was calculated using ImageJ software (National Institutes of Health). A correlation 
analysis between percentage areas of tracer binding and positive immunostaining was 
conducted using Pearson simple correlation. 
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Cell penetration and binding study 
   Tau construct (K18ΔK280) gene was amplified by PCR using pET-3a K18ΔK280 (Life 
Technologies) as a template. The K18ΔK280 PCR product was digested by XhoI and BamHI 
(Takara-Bio, Shiga, Japan) and subcloned into pmkate2-N vector (Evrogen JSC, Moscow, 
Russia). Sequences were confirmed by DNA sequencing (Perkinelemer ABI Model 3100). 
Tau-mKate2 was expressed in HEK293 cells by transient transfection using Lipofectamine 
LTX (Life Technologies) with the addition of a protease inhibitor, Epoxomicin (Kindly gifted 
from Dr. Takafumi Hasegawa) and 1 μM of THK-5105, -5117, -523, or thioflavin-S. At 24 h 
after the transfection, the cells were briefly washed and then mounted with medium 
containing 4’-6-diamidino-2-phenylindole (DAPI) (SouthernBiotech, Birmingham, AL) for 
nuclear staining, images were acquired by a Nikon C2Si confocal microscope (Tokyo, Japan).  
 
Biodistribution in mice 
The experimental protocol of animal study was approved by the Ethics Committee of 
Tohoku University School of Medicine. 18F-labeled tracers (1.1–6.3 MBq) were injected into 
the tail vein of male ICR mice (n = 20, mean weight, 28–32 g). Mice were then sacrificed by 
decapitation at 2, 10, 30, 60, and 120 min post injection (p.i.). The brain, blood, liver, kidney, 
and femur were removed and weighed, and radioactivity was counted with an automatic 
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γ-counter. The percent injected dose per gram of tissue (%ID/g) was calculated by comparing 
tissue counts to tissue weight. Each %ID/g value is expressed as a mean ± SD of 4 separate 
experiments. 
 
Results 
3-1. Radiosynthesis 
   All labeled compounds ([18F]THK-5105, [18F]THK-5117, [18F]THK-523, (Fig. 11) 
[18F]FDDNP, and [11C]PiB) were synthesized in >97% radiochemical purities after HPLC 
purification. The decay-corrected average radiochemical yields of [18F]THK-5105 and 
[18F]THK-5117 were 48%. This value is a good radiochemical yield for PET imaging 
radiotracers. The specific activities of 18F-labeled compounds ranged from 37 to 110 
GBq/μmol, corrected at the end of synthesis. The mean specific activity of [11C]PiB was 35 
GBq/μmol. 
 
3-2. Binding affinity for in vitro generated fibrils and AD brain homogenates 
To characterize the binding properties of 2-arylquinoline derivatives, in vitro radioligand 
binding assays for synthetic Aβ42 and truncated tau construct (K18ΔK280) fibrils were 
conducted. Although only a single class of [18F]THK-5105 binding sites was identified on 
Aβ42 fibrils, 2 classes of [18F]THK-5105 binding sites were identified on K18ΔK280. As 
shown in Table 2, the KD for the first class of K18ΔK280 binding sites was 1.45 nM, 
indicating that higher binding affinity to tau fibrils than to Aβ42 fibrils (KD = 35.9 nM). 
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Further competitive binding assays with [18F]THK-5105 displayed high binding affinity of 
phenylquinoline derivatives to tau fibrils (Fig. 12). The Ki for THK-5117 was 10.5 nM, 
indicating that THK-5117 has higher affinity for tau fibrils than THK-523 (Ki = 59.3 nM). In 
contrast, the Ki for FDDNP was 263 nM. In binding assays using mesial temporal brain 
homogenates containing a high density of tau (1,075 pmol/g) and moderate density of Aβ 
(434 pmol/g), both [18F]THK-5105 (KD = 2.63 nM, Bmax = 358 pmol/g tissue) and 
[18F]THK-5117 (KD = 5.19 nM, Bmax = 338 pmol/g tissue) showed higher affinity for mesial 
temporal brain homogenates than [18F]THK-523 (KD = 86.5 nM, Bmax = 647.1 pmol/g tissue) 
(Fig. 13a-c). 
 
3-3. In vitro cell penetration and binding assay 
   Since NFTs are intracellular protein deposits in AD brain, tau PET tracer needs to 
penetrate the cell membrane and to bind to protein aggregates in the cells. To construct cell 
permeability assay, K18ΔK280 tau construct was fused to mKate2, which is a super bright 
far-red fluorescence protein (Tau-mKate2) (Fig. 14). Tau-mKate2 was expressed in HEK293 
cells by transient transfection with proteasome inhibitor to induce readily aggregation. 49) 
Tau-mKate2 aggresome-like structures were observed, which was previously reported. 49,50) 
After incubation with THK compounds (-5105, -5117, -523), these compounds co-localized 
Tau-mKate2 aggregates (Fig. 15), indicating that THK compounds can permeate the cell 
membrane and bind to intracellular tau protein aggregates. 
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3-4. Tissue staining, autoradiography, and immunohistochemistry 
   Since THK-5105 and THK-5117 are fluorescence compounds, tissue staining was 
performed to confirm the binding to tau pathology. Both THK-5105 and THK-5117 clearly 
stained NFT, neuropil threads and dystrophic neuritis, which was confirmed by tau 
immunostaining (Fig. 16). To investigate the binding ability and selectivity of these tracers, in 
vitro autoradiography were performed using the serial sections of mesial temporal brain 
sections from a healthy control subject and two AD patients. The laminar distributions of 
[18F]THK-5105 and [18F]THK-5117 were observed in the deep layer of grey matter in AD 
brain tissue (Fig. 17a, b). There was high tracer accumulation of these tracers, not [11C]PiB, in 
the CA1 area of the hippocampus (Fig. 17c), which is reported as the most frequent site for 
tau pathology in AD. 51) These tracer distributions were similar to Gallyas-Braak staining and 
tau immunostaining (Fig. 17d, e, g, h), but not with the distribution of [11C]PiB and Aβ 
immunostaining (Fig. 17f, i). In contrast, no significant accumulation of [18F]THK-5105 and 
[18F]THK-5117 was observed in mesial temporal brain sections from a health control subjects 
(Fig. 17j, k). 
To further access the regional differences of tracer binding in AD brain, [18F]THK-5105 
autoradiography was performed using AD hemibrain sections and compared with [11C]PiB. 
[18F]THK-5105 densely accumulated in the grey matter of the hippocampus, parahippocampal 
gyrus, fusiform gyrus, inferior and middle temporal gyri, insula, and cingulate gyrus (Fig. 
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18a), while the modest binding was observed in the pariental, which was similar to tau 
immunohistochemistry (Fig. 18b). The pattern of tracer distribution correlated with the known 
distribution of tau pathology, but not with the known distribution of Aβ nor the binding of 
[11C]PiB (Fig. 18c). In addition, quantitative analyses of these images showed that significant 
correlation of [18F]THK-5105 binding with tau immunostained areas, but not with the areas of 
Aβ immunostaining (Fig. 18d). In contrast, [11C]PiB bindings showed good correlation with 
Aβ deposition but not with tau deposition. 
 
3-5. Pharmacokinetics in mice 
All tested compounds exhibited sufficient amounts of tracer uptake in the mouse brain 
immediately after intravenous administration. Compared with [18F]THK-523, new THK 
compounds showed significantly higher brain uptake at 2 min p.i. (Table 3). [18F]THK-5105 
showed the highest brain uptake. In addition, clearance of these derivatives from normal brain 
tissue was faster than that of [18F]THK-523 and [18F]FDDNP (Table 3). The brain uptake 
ratio at 2 min versus 60 min was highest for [18F]THK-5117, followed by [18F]THK-5105, 
[18F]FDDNP, and [18F]THK-523. After injection of [18F]THK-5105 and [18F]THK-5117, the 
regional tracer uptake in the liver was highest at 10 min p.i., and the tracer was then slowly 
washed out from the body (Fig. 19). Compared with [18F]THK-5105, [18F]THK-5117 tended 
to have faster clearance from the brain, blood, liver, and kidney. No remarkable accumulation 
of [18F]THK-5105 and [18F]THK-5117 was observed in the bone. 
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Discussion 
   These findings suggests that [18F]THK-5105 and [18F]THK-5117 are promising candidates 
as tau imaging PET radiotracers. [18F]THK-523 selectively bound to tau fibrils and tau 
pathology in AD brain sections, but it showed low contrast of tau pathology due to high white 
matter binding, and insufficient brain uptake. 37, 52) Therefore, I optimized and then obtained 
novel 18F-labeled 2-arylquinoline derivatives ([18F]THK-5105 and [18F]THK-5117). In this 
chapter, preclinical evaluations of these tracers were performed. 
Although previous saturation analysis in Chapter 2 showed the high binding affinity of 
[18F]THK-523 for tau fibrils (KD = 1.99 nM), the current competition assay demonstrated 
relatively lower binding affinity of THK-523 for tau fibrils (Ki = 59.3 nM) than THK-5105 
(Ki = 10.5 nM). [18F]THK-5105 showed higher affinity for tau pathology than for Aβ 
pathology in AD brain sections. Most amyloid imaging agents potentially bind to both tau and 
Aβ fibrils, because both protein fibrils share a common β-sheet secondary structure. To ensure 
the specificity of these compounds as tau-selective PET probes, the binding affinity to Aβ 
fibrils should be low the in vivo detection threshold. In vitro binding assays indicated that 
[18F]THK-5105 possessed higher affinity for tau fibrils (KD = 1.45 nM) rather than Aβ fibrils 
(KD = 35.9 nM). Binding selectivity of THK-5105 for tau fibrils was around 25 times more 
potent than for Aβ fibrils. A simulation study estimated that a 20-50-fold selectivity for tau 
over Aβ will be required to visualize tau pathology in vivo. 53) This KD would allow selective 
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detection of tau pathology, because the usual required KD values for imaging Aβ are below 20 
nM. However, KD value for imaging tau deposits is still unknown. Considering that the 
concentrations of tau are about an order of magnitude lower than those of Aβ, the KD for tau 
should be well below 20 nM, in the low nanomolar range, to allow sensitive detection of tau 
pathology. In that respect, both [18F]THK-5105 and [18F]THK-5117 to tau fibrils may be 
sufficient for in vivo detection of tau pathology in the brain. However, in vitro binding assay 
data should be carefully interpreted, because the structural conformation of synthetic tau 
fibrils does not fully correlate with the structure of NFTs and neuropil threads in the human 
brain. In Chapter 1, the binding affinity of various tracers using in vitro generated Aβ and tau 
fibrils was evaluated, but sometimes in vitro binding data contradicted the binding data using 
human brain tissues.  
In vitro binding assays using AD brain homogenates are generally used to measure the 
binding affinity of Aβ imaging radiotracers to SPs or NFTs and the number of binding sites in 
real AD pathology. For Aβ imaging radiotracers, given the high concentration of potential 
binding sites of Aβ in AD brain (0.4-1.9 μM), 54) this would mean a radiotracer with a KD of 
about 200 nM (Bmax/KD = 2 μM/200 nM = 10). However, the KD values against AD brain 
homogenates of recent successful Aβ imaging radiotracers are below 10 nM, 55) that is, BPs 
with around 1000. The potential binding sites of PHF-tau (0.05-0.2 μM) were fewer than that 
of Aβ in the brain of AD patient. 56) This would mean a tau PET radiotracer with KD range 
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between 5-20 nM. In this study, the KD values for high-affinity sites of AD mesial temporal 
homogenates were KD = 2.63 nM for [18F]THK-5105 and KD = 5.19 nM for [18F]THK-5117. 
The binding affinities were higher than that for [18F]THK-523 and appear to be sufficient for 
the in vivo detection of AD pathology in the mesial temporal region at tracer doses. 
Furthermore, the binding potential (Bmax/KD ratios) of [18F]THK-5105 and [18F]THK-5117 for 
the mesial temporal brain homogenate from AD were 136.1 and 65.1, respectively, which 
fulfills the criteria (Bmax/KD ratio > 10) for a good neuroimaging agent. 20)  
In vitro autoradiography using human brain tissues are considered more reliable for 
evaluating the binding selectivity of radiotracers at tracer dose. Autoradiography studies using 
human brain sections demonstrated the preferential binding of [18F]THK-5105 and 
[18F]THK-5117 to tau protein deposits in AD brain. A high accumulation of [18F]THK-5105 
and [18F]THK-5117 were observed in the CA1 region of AD hippocampus, which contained 
substantial amounts of NFTs and neuropil threads. In addition, these tracers clearly visualized 
the laminar distribution of PHF-tau in pri-α layer of the transentorhinal and temporal cortices, 
that is typically observed in the AD brain. 8) The distribution pattern of these tracers binding 
in AD brains was different from that of Aβ imaging tracers such as PiB and BF-227, which 
showed diffuse punctate distribution in broad neocortical grey matter and less tracer 
distribution in the mesial temporal region in Chapter 2. These findings strongly suggest that 
the binding properties of [18F]THK-5105 and [18F]THK-5117 are different from those of 
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currently available Aβ PET probes. Compared with [18F]THK-523, 52) [18F]THK-5105 and 
[18F]THK-5117 showed higher contrast of tau pathology in autoradiographic images. These 
findings most likely reflect the increased binding affinity to PHF-tau by methylation of the 
amino group. Similar findings were previously reported in arylbenzothiazole derivatives. 20) 
Compared with [18F]THK-5105, [18F]THK-5117 showed lesser tracer binding in the grey 
matter containing high density of Aβ plaques, suggesting low binding affinity to Aβ, and high 
selectivity to tau. [18F]THK-5105 tends to show higher signals in the grey matter, and some of 
the images of [18F]THK-5105 binding showed the patchy pattern as observed for [11C]PiB 
binding. One possible reason for this is the binding of [18F]THK-5105 to tau protein in 
dystrophic neurites. Another possible reason is binding of [18F]THK-5105 to Aβ fibrils. 
However, the latter explanation seems unlikely given that [18F]THK-5105 binding, as clearly 
shown in Fig. 18, was correlated with tau, and not Aβ deposits. 
   Since tau pathologies are mainly intracellular aggregates, tau PET radiotracer has to be 
cross the cell membrane, either by active transport or passive diffusion, as well as the blood 
brain barrier (BBB). Cell permeability test using tau-mKate2 expressing cells suggested that 
THK compounds could penetrate cell membrane and bind to tau aggregate in the cells, 
indicating that THK-5105 and THK-5117 satisfy one of the prerequisites for tau PET 
radiotracer.  
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   The optimization of pharmacokinetics is an important aspect in the development of a PET 
tracer. 57) [18F]THK-5105 and [18F]THK-5117 fulfilled the criteria of appropriate Log P value 
(LogP = 1-3) for brain entry. 58) In mice, these tracers showed sufficient brain uptake and 
washout from normal brain tissue. [18F]THK-5105 and [18F]THK-5117 exhibited higher initial 
brain uptake in normal mice (> 6 %ID/g at 2 min) than [18F]THK-523. These values, which 
are equivalent to over 100% injected dose index in a 25 g mouse, meet the prerequisites for 
useful PET imaging agents. 59) The 2 to 60 min ratio of radioactivity concentrations for 
[18F]THK-5117 was 23.1, indicating faster washout from normal brain for these compounds 
than for other currently available 18F-labeled tracers such as FDDNP (2.91) , florbetaben 
(4.83), and florbetapir (3.90). 60), 61) Although 18F-labeled tracers potentially defluorinate and 
accumulate in the bone, [18F]THK-5105 and [18F]THK-5117 showed no remarkable 
accumulation in the bone.  
In conclusion, [18F]THK-5105 and [18F]THK-5117 should be considered as promising 
candidates for PET tau imaging radiotracers. First-in-human PET studies of [18F]THK-5105 
and [18F]THK-5117 are ongoing in University of Melbourne and Tohoku University, 
respectively. Preliminary data suggested that both tracers could distinguish between AD 
patients and healthy controls. The retention patterns of both tracers followed the known 
distribution of PHF-tau in AD and was obviously different from those of [11C]PiB. Further 
clinical studies are needed to validate these tracers, but these initial findings suggest both 
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[18F]THK-5105 and [18F]THK-5117 are promising tau PET radiotracers for in vivo detection 
of tau pathology in AD. 
In the future, these radiotracers will help us to understand the role of tau pathology in AD 
progression and neurodegeneration by the assessment of spatial and temporal patterns of tau 
load in vivo. Furthermore, tau PET imaging would allow us to accurate diagnosis of dementia, 
preclinical detection of tau pathology, tracking disease progression, prediction of future 
cognitive decline, subject selection for anti-tau trials, and evaluation of treatment efficacy of 
anti-therapy. 
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Conclusions 
 
   The central goal of the thesis was to characterize the binding and pharmacokinetic 
profiles of novel 2-arylquinoline derivatives, [18F]THK-523, [18F]THK-5105 and 
[18F]THK-5117 as potential candidates for selective tau radiotracer. In Chapter 1, the binding 
properties of [18F]THK-523 were compared with those of previously reported amyloid 
imaging tracers. The selective binding ability of [18F]THK-523 for tau aggregates in AD brain 
sections was confirmed. In Chapter 2, the binding and pharmacokinetic properties of 
optimized compounds, [18F]THK-5105 and [18F]THK-5117, were further investigated. These 
compounds showed high binding affinity and selectivity of these compounds for tau deposits 
in AD brain samples and better pharmacokinetics in mice than [18F]THK-523. From these 
results, [18F]THK-5105 and [18F]THK-5117 are considered as promising PET tracer for 
imaging tau deposits in AD patients. 
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Figure legends 
Fig. 1: Neuropathological hallmarks of Alzheimer’s disease: Senile plaques (a), and 
Neurofibrillar tangles (b), which can be detected by amyloid-β or tau immunohistochemistry. 
 
Fig. 2: Different stages of NFT progression and plaques progression in Alzheimer’s disease. 
NFT progression classifies mainly three stages; Stage I and II (Transenthorinal stage), Stage 
III and IV (Limibic stage) and Stages V-IV (Isocortical stage). Plaques progression classifies 
Stage A, Stage B, and Stage C. Stage V-IV (NFT) and Stage C (Plaques) are the most severe 
stages. These figures adapted from Braak & Braak, 1997; Serrano-Pozo et al, 2011.  
 
Fig. 3: Chemical structures of [11C]PiB, [18F]FDDNP, [11C]BF-227, and [18F]THK-523 
 
Fig. 4: Time course of Alzheimer’s pathological changes and clinical changes. The earliest 
change is the deposition of amyloid-β in Alzheimer’s disease. The deposition of tau is close to 
synaptic dysfunction, neuronal loss and cognitive decline, but it occurs before them. 
 
Fig. 5: Radiosynthesis scheme of [11C]PiB, [11C]BF-227, [18F]BF-227, [18F]FDDNP, and 
[18F]THK-523 
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Fig. 6: Diagram of human tau isoforms and construct (K18ΔK280) used in this study. (a) The 
bottom bar represents the longest human tau isoform (441 amino acids) in the central nervous 
system (CNS). The top one represents short fragment construct K18 containing K18ΔK280 
mutation, which was observed in FTDP-17. (b) Electron microscopy images of 
K18ΔK280-tau fibrils. Scale bars represent 100 μm 
 
Fig. 7: Autoradiographic and immunofluorescent images of serial lateral temporal sections 
from a patient with Alzheimer disease (69-year-old man). The labeling patterns of [11C]PiB 
and [18F]BF-227 were consistent with that of Aβ immunohistochemistry. Conversely, 
[18F]THK-523 showed a belt-like labeling pattern in the inner layer of the grey matter, 
consistent with tau immunostaining. [18F]FDDNP did not bind to any region in this brain 
section. Arrowheads represent the laminar distribution of tau pathology. 
 
Fig. 8: Comparison of [11C]PiB and [18F]THK-523 autoradiography with the Aβ and tau 
immunostaining in the frontal brain sections from 3 patients with Alzheimer disease (AD1, 2, 
3). Both [11C]PiB (a-c) densely accumulated in the grey matter, closely resembling the pattern 
of Aβ immunohistochemistry using the 6F/3D antibody (d-f). [18F]THK-523 (g-i) did not 
accumulate in the grey matter, which was correlated with no remarkable staining with anti-tau 
antibody AT8 (j-l). 
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Fig. 9: Comparison of [
11
C]PiB and [
18
F]THK-523 autoradiography with Aβ and tau 
immunostaining images in the mesial temporal brain sections from 3 patients with Alzheimer 
disease (AD1, 2, 3). [
11
C]PiB (a-c) did not accumulate in hippocampal CA1 area which 
contained low density of Aβ (d-f). In contrast, the accumulation of [
18
F]THK-523 was 
observed in hippocampal CA1 area (m-o, open arrow heads), which closely resembled AT8 
immunoreactivity (g-i, open arrow heads). In addition, the band-like labeling pattern of 
[
18
F]THK-523 in the inner layer of temporal cortex (g-i) was closely similar to that of AT8 
immunostaining (j-l). High magnification images of the mesial temporal sections from case 
AD3 were shown in the panel m-s. Many clusters of [
18
F]THK-523 binding in the entorhinal 
cortex (ERC) was consistent with Gallyas silver staining (m n, arrows). Close-up images of 
m demonstrated that numerous NFTs were located in the layer pre-α of the ERC (insert in o). 
The band-like distribution of [
18
F]THK-523 in the layer pri-α of the ERC also resembled the 
labeling pattern of Gallyas silver staining (m, filled arrow head) as well as AT8 
immunoreactivity (q, filled arrow head). [
11
C]PiB binding (r) was also present in the ERC, 
but obviously different from [
18
F]THK-523 binding (n) and similar to 6F/3D immunostaining 
pattern (s). Lake-like amyloid in the presubicular region (s) was labeled with [
11
C]PiB, but not 
with [
18
F]THK-523. Close-up image of r indicated that Aβ plaques (insert in p) located in the 
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layer pre-β and pre-γ were intensely labeled with [
11
C]PiB (r). Asterisks denote the same large 
blood vessel in panel o and p. Scale bar = 100 μm  
 
Fig. 10: Radiosynthesis scheme of 18F-2-arylquinolines  
 
Fig. 11: Chemical structures of [18F]THK-5105, [18F]THK-5117, and [18F]THK-523. 
 
Fig. 12: Competitive inhibition of [18F]THK-5105 binding by 2-arylquinolines and FDDNP to 
tau protein fibrils. Ki values for inhibition of [18F]THK-5105 binding to tau are shown. 
 
Fig. 13: In vitro saturation binding curve of [18F]THK-5105 (a), [18F]THK-5117 (b), and 
[18F]THK-523 (c) to mesial temporal brain homogenate of an AD patient. 
 
Fig. 14: Diagram of tau construct (K18ΔK280) fused to mKate 2 (Tau-mKate2) used in this 
study. The bottom bar represents the longest human tau isoform (441 amino acids) in the 
central nervous system (CNS). The top one represents short fragment construct K18 
containing K18ΔK280 mutation, which was observed in FTDP-17. 
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Fig. 15: In vitro cell penetration assay of fluorescence compounds, THK-5105, -5117, -523, 
and thioflavin-S.  
 
Fig. 16: Neuropathologic staining of brain sections from AD patients. Neufibrillary tangles 
and neuopilthreads were clearly stained with THK-5105 and THK-5117. These staining were 
consistent with tau immunostaining in same sections. Images are representative of at least 8 
brain sections in tissue staining experiments. Scale bars represent 100 μm. 
 
Fig. 17: Autoradiographic images of [18F]THK-5105 (a), [18F]THK-5117 (b), and [11C]PiB (c) 
binding in mesial temporal section from an AD patient. High magnification images of the 
mesial temporal sections were shown in the panel d-f. The high density accumulation of 
[18F]THK-5105 and [18F]THK-5117 in the CA1 (filled arrow head) and the ERC (filled 
arrow) also resembled the labeling pattern of Gallyas silver staining (g) as well as AT8 
immunoreactivity (h). [11C]PiB binding (f) was also present in the ERC, but obviously 
different from [18F]THK-5105 and [18F]THK-5117 binding (d, e) and similar to 6F/3D 
immunostaining pattern (i). No significant accumulations of these tracers (a:[18F]THK-5105, 
b:[18F]THK-5105) were observed in the mesial temporal section from an control subject. 
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Fig. 18: Autoradiographic of hemibrain sections from AD patient with [18F]THK-5105 (a) and 
tau immunostaining (b) and [11C]PiB (c) in neighboring section. Region-of-interest analysis 
indicated that percentage areas of [18F]THK-5105 binding (line plots) were significantly 
correlated with percentage areas of tau immunostaining (gray bars) but not with that of Aβ 
immunostaining (white bar). CG = cingulate gyrus; HIP = hippocampus; FUG = fusiform 
gyrus; IHC = immunohistochemistry; INS = insula; ITG = inferior temporal gyrus; MTG = 
middle temporal gyrus; PCL = paracentral gyrus; PHG = parahippocampal gyrus; POG = 
postcentral gyrus; PRG = precentral gyrus; SFG = superior frontal gyrus; STG = superior 
temporal gyrus. 
 
Fig. 19: Time-activity curves after intravenous administration of [18F]THK-5105 (a) and 
[18F]THK-5117 (b) in mice.  
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List of Abbreviations 
 
A Alanine (amino acid) 
Alzheimer’s disease AD 
APP Amyloid precursor protein 
Aβ Amyloid-β 
ARG Autoradiography 
BBB Blood brain barrier 
Bmax Maximum number of binding sites 
BP Binding potential 
BSA Bovine serum albumin 
CSF Cerebrospinal fluid 
CT Computed tomography 
Δ Delta (elimination) 
DAPI 4’-6-diamidino-2-phenylindole 
DMSO Dimethylsulfoxide 
DTT Dithiothreitol 
E Glutamate (amino acid) 
ELISA Enzyme-linked immunosorbent assay 
 
 
ERC Entorhinal cortex 
FTLD Frontotemporal lobar degeneration 
HPLC High Performance Liquid Chromatography 
K Lysine (amino acid) 
KD Dissociation equilibrium constant 
Ki Inhibition constant 
K18 Tau fragment (microtubule-binding repeat) 
ID Injected dose 
in vitro Peformed in tuebes 
in vivo Peformed in living  
MRI Magnetic resonance imaging 
NFTs Neurofibrillary tangles 
PBS Phosphate buffered saline 
PET Positron emission tomography 
PHF Paired helical filament 
PiB Pittsuburgh compound B 
PSEN Presenilin 
SAR Strucutre-activity relationship 
SPs Senile plaques 
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